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Heart failure, typically a progressive disease, now affects 22
million people worldwide.1 Over the past 50 years great strides
have been made in developing treatments for end-stage heart
failure, but these measures remain largely palliative.2 The
diagnosis of heart failure is associated with a poor prognosis,
with only 35% of patients surviving 5 years after the first
diagnosis.3 For patients with the most advanced phase of heart
failure, heart transplantation has been the only means of
improving quality of life and survival, but this option is
available to only a fraction of those needing it because of the
shortage of donors.2 There is therefore a need to identify new
and more effective treatments for heart failure.
Recent research findings have suggested that pentoxifylline
may have beneficial effects when added to the standard
treatment for heart failure.4-9 Pentoxifylline, a purine derivative,
is a peripheral vasodilator agent that is thought to work by
improving the flow properties of blood; it improves
erythrocyte flexibility, reduces platelet aggregation, reduces
blood viscosity and improves microcirculatory blood flow.
Pentoxifylline is also an inhibitor of pro-inflammatory
cytokines, such as tumour necrosis factor-alpha (TNF-α), and it
inhibits apoptosis in different human cell types in vitro and in
vivo; high plasma TNF-α levels and increased apoptosis of
cardiac cells may contribute to disease progression and
mortality in heart failure.10,11 The vasodilatory, anti-
inflammatory and anti-apoptotic properties of pentoxifylline
have made it a prime candidate for the treatment of heart
failure.  
We conducted a systematic review of the world literature to
determine whether the addition of pentoxifylline to standard
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Background. Recent trials have indicated a beneficial effect of
pentoxifylline on measures of inflammation and markers of
cardiac dysfunction in people with heart failure. However, it
is uncertain whether pentoxifylline should be used routinely
in the management of heart failure. 
Objective. To determine the effectiveness of pentoxifylline in
heart failure.
Design. Systematic review of randomised controlled trials.
Methods. We searched MEDLINE (1 January 1966 - 20
November 2004), the Cochrane Controlled Trials Register
(issue 4, 2004), and reference lists of related papers, for
randomised controlled trials of pentoxifylline in the treatment
of heart failure. Prospective, randomised, double-blind
controlled trials were sought for inclusion in the study. The
two reviewers independently assessed trial quality and
extracted data, which were analysed using RevMan statistical
software. The following outcome measures were evaluated: (i)
New York Heart Association (NYHA) functional class; (ii) left
ventricular ejection fraction (LVEF); (iii) frequency of
hospitalisation; and (iv) death from all causes.
Results. Four studies with a total of 144 participants met the
inclusion criteria. Statistical pooling (or meta-analysis) was
not performed owing to the significant clinical heterogeneity
and differences in reporting of the outcomes in the included
studies; instead, the trials were analysed separately for the
outcomes of interest. The four studies tested the use of
pentoxifylline versus placebo in patients with heart failure of
varying aetiology (idiopathic dilated cardiomyopathy, 3
studies; ischaemic cardiomyopathy, 1 study). In 2 of the
idiopathic dilated cardiomyopathy studies, patients were
classified as NYHA class II or III, while the study population
in another idiopathic cardiomyopathy study was in NYHA
class IV. The trial of patients with ischaemic cardiomyopathy
included patients in NYHA functional classes I - IV. The use
of pentoxifylline was associated with significant improvement
in symptoms (i.e. NYHA functional class) and cardiac
function (i.e. LVEF) in 3 out of 4 studies. The beneficial effect
on symptoms of heart failure and cardiac function was seen
in all grades of severity of heart failure and in patients with
ischaemic and idiopathic dilated cardiomyopathy. All 4
studies showed a trend towards reduction of mortality, but
this effect was not statistically significant. The effect of
pentoxifylline on the frequency of hospitalisation has not
been tested in randomised controlled trials.
Interpretation. Pentoxifylline may have a beneficial effect on
NYHA functional class, ejection fraction and mortality in
heart failure, but published trials are too small to provide
conclusive evidence.  There is a need for large, placebo-
controlled trials of pentoxifylline in heart failure, involving a
diverse group of patients with regard to cause and severity of
heart failure.
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treatment leads to improvement in symptoms, cardiac function,
frequency of hospitalisation and death rate in people with
heart failure. 
Methods
We considered randomised placebo-controlled trials comparing
the use of pentoxifylline with placebo in patients of all ages
with a clinical diagnosis of heart failure.  We examined the
effect of pentoxifylline on the following outcome measures: (i)
New York Heart Association (NYHA) functional class; (ii) left
ventricular ejection fraction (LVEF); (iii) frequency of
hospitalisation; and (iv) death from all causes.
Studies selected for review were identified from the
following sources: (i) MEDLINE (1 January 1966 - 20
November 2004); (ii) the Cochrane Controlled Trials Register
(issue 4, 2004); and (iii) reference lists of existing studies of
pentoxifylline in the treatment of heart failure.
Two reviewers (KB and BMM) independently searched the
literature and identified possible trials for review; we were
looking for prospective double-blind randomised controlled
trials. Studies that were not randomised controlled trials were
excluded. Information from each study was entered into a data
extraction form that included details of the authors, duration of
the study, nature of allocation concealment and double
blinding, and outcomes of each trial. Data were analysed using
the RevMan (version 4.1) statistical software for derivation of
the following statistical estimates of effect: odds ratios (ORs)
for dichotomous outcomes or weighted mean differences
(WMDs) for continuous outcomes, 95% confidence intervals
(CIs) and p-values.12
A 5-point quality scale was used to assess the
methodological quality of the included studies (Table I). The 5-
point quality scale included the generation of the allocation
sequence (2 points — computer-generated random numbers or
similar; 1 point — not described; 0 point — quasi-randomised
trial); double-blinding (2 points — identical placebo tablets or
similar; 1 point — not described; 0 point — no blinding or
inadequate method, such as tablets versus injections or
similar); and follow-up (1 point — number and reasons for
dropouts and withdrawals described; 0 point, number and/or
reasons for dropouts and withdrawals not described). The
quality score was ranked as low (≤ 2 points) or high (≥ 3
points).13
The included studies were analysed separately and not
combined in a meta-analysis, as initially planned, for the
following reasons: (i) considerable clinical heterogeneity
existed among selected trials, for example patients differed
from trial to trial with regard to cause of heart failure (e.g.
peripartum cardiomyopathy versus idiopathic dilated
cardiomyopathy), severity of symptoms as assessed by NYHA
functional class, and available treatments (e.g. pre-β-blocker
versus β-blocker era); and (ii) trials reported data in different
forms (e.g. the trials by Sliwa et al. (1998),4 Skudicky et al.
(2000),5 and Skudicky et al. (2001)6 reported data in a
dichotomous form, while data in the trials by Sliwa et al. (2002)7
and Sliwa et al. (2004)8 were reported as continuous measures),




Four studies with a sample size varying from 18 to 49 and a
total of 144 participants met the inclusion criteria.4-7,9 According
to the published reports, the study by Skudicky et al.
5
(2000)
was an extension study of the trial by Sliwa et al.
4
(1998), thus
the 2 trials were reviewed as 1 to avoid double counting of the
study participants. Details of studies included in this
systematic review are given in Table I.  All trials involved
patients of black African descent and the same group of
investigators in Johannesburg, South Africa.  Patients in 2 of
the studies were classified as either NYHA functional class II or
III.4-6 In 1 of the studies, they were classified as functional class
IV,7 and in the other study patients from all functional class
groupings were included.9 Patients in 3 of the trials were
diagnosed with idiopathic dilated cardiomyopathy,4-7 while
those in the fourth study had ischaemic cardiomyopathy.9 All
patients exhibited LVEFs of ≤ 40%. The length of follow-up was
6 months in all studies4-6,9 except 1.7 The outcomes measured in
the trials are indicated in Table I.  None of the trials reported
on the frequency of hospitalisation as an outcome measure. 
Methodological quality of included studies
The studies included in this systematic review were generally
of good methodological quality (Table I), but there was
variation in reporting the method of randomisation and
concealment of allocation sequence.  In 2 studies, the
randomisation list was computer-generated by the Statistics
Department at the University of the Witwatersrand, with an
equal number assigned to receive pentoxifylline and placebo.4,5,9
The remaining 2 trials did not specify randomisation
techniques.6,7 The selected trials were reported to be double-
blind studies, but the method of allocation concealment was
not given in any of the studies.  The Skudicky et al.6 (2001) trial
specified loss to follow-up and utilised intention-to-treat
analysis. Loss to follow-up was specified in the Sliwa et al.4
(1998) trial, but intention-to-treat analysis was not employed.
Loss to follow-up was not reported in the remaining trials, nor
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Table I. Studies included in this review
Study grading 
(5-point quality 
Study Patients N Interventions Outcomes grading scale)*
Sliwa et al.4 (1998) Patients with idiopathic 28 Intervention: pentoxifylline NYHA functional class; 2 + 2 + 1 = 5
dilated cardiomyopathy 400 mg TID for 6 months left ventricular function high-quality
and congestive heart failure (in addition to digoxin, ACE (systolic and diastolic); score
classified as NYHA functional inhibitors and diuretics, initiated left ventricular dimen-
class II or III, with a LVEF of at least 4 months before sions; LVEF
≤ 40%, aged 18 - 70 years and randomisation)
in sinus rhythm
Skudicky et al.5  (2000) Patients with idiopathic 49 Intervention: pentoxifylline 400 mg LVEF; TNF-alpha and 2 + 2 + 1 = 5
dilated cardiomyopathy TID for 6 months (in addition to Fas/APO-1 plasma high-quality score
in NYHA functional conventional therapy of digoxin, concentrations; left
class II or III with a LVEF ACE inhibitors and diuretics) ventricular diameter
of ≤ 40%
Skudicky et al.6 (2001) Patients with idiopathic 39 Intervention: pentoxifylline 400 mg NYHA functional class; 1 + 2 + 0 = 3
dilated cardiomyopathy TID for 6 months (in addition to left ventricular function high-quality score
in NYHA functional digoxin, ACE inhibitors and (systolic and diastolic);
class II or III with a LVEF carvedilol, initiated 3 months left ventricular size; 
of < 40%, aged 18 - 70 years before randomisation) exercise tolerance
and in sinus rhythm
Sliwa et al.7 (2002) Patients with idiopathic 18 All patients received intravenous NYHA functional class; 1 + 2 + 0 = 3
dilated cardiomyopathy dobutamine for at least the first LVEF; left ventricular high-quality score
aged ″  18 years with NYHA 72 hours of the study dimensions; plasma 
class IV heart failure, a LVEF cytokine and Fas/
″ 40%, a left ventricular end APO-1 levels; 
diastolic diameter of > 55 mm, haemodynamics
and in sinus rhythm
Control: matching placebo
and conventional therapy (of diu-
retics, digoxin and ACE inhibitors).
Sliwa et al.9 (2004) Patients with ischaemic 38 All patients received optimal LVEF; NYHA functional 2 + 2 + 0 = 4
cardiomyopathy, aged 18 - 70 medical therapy for 3 months class; clinical assessment; high-quality score
years with NYHA class I - IV before randomisation plasma TNF-α, Fas/APO-1, 
heart failure, a LVEF ″  40%, high-sensitivity C-reactive protein and
and in sinus rhythm NT-pro BNP levels; left
ventricular dimensions
Control: matching placebo
(in addition to ACE inhibitors,
β-blockers, diuretics and
spironolactone)
N = number of participants in a trial; NYHA = New York Heart Association; LVEF =  left ventricular ejection fraction; TID = three times daily; ACE = angiotensin-converting enzyme; 
* See methods section for an explanation of the trial grading method.
Intervention: pentoxifylline
400 mg TID for 6 months
(in addition to ACE inhibitors,
β-blockers, diuretics
and spironolactone)
Intervention: pentoxifylline 400 mg
TID for 1 month (in addition to
conventional therapy of diuretics,
digoxin and ACE inhibitors)
Control: matching placebo and
conventional therapy (of digoxin,
ACE inhibitors and diuretics)
Control: matching placebo 
(in addition to digoxin, ACE 
inhibitors and carvedilol,
initiated 3 months prior to
randomisation)
Control: matching placebo and
conventional therapy (of digoxin,
ACE inhibitors and diuretics,
initiated at least 4 months before
randomisation) for 6 months
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Main findings
Improvement in NYHA functional class
In the Sliwa et al.4 (1998) trial comparing the use of
pentoxifylline and placebo in 28 idiopathic dilated
cardiomyopathy patients in NYHA class II - III heart failure,
pentoxifylline was associated with an improvement in NYHA
functional class. However, this effect was not statistically
significant (OR 3.33, 95% CI: 0.69 - 16.02, p = 0.13).  However, a
statistically significant improvement in NYHA functional class
was found with the use of pentoxifylline when the number of
patients was increased to 39 in this study (OR 15.79, 95% CI
2.80 - 89.00, p = 0.02).5 A similar result was found in 18 patients
with idiopathic dilated cardiomyopathy in  NYHA class IV
heart failure (WMD 1.00, 95% CI: 0.26 - 1.74, p = 0.009).7 These
findings in patients with idiopathic dilated cardiomyopathy
were subsequently extended to patients with heart failure due
to ischaemic cardiomyopathy; 38 such patients in NYHA class
I - IV heart failure had statistically significant improvement in
effort tolerance following the addition of pentoxifylline (WMD
–0.90, 95% CI: –1.35 - 0.45, p = 0.00009).9
Improvement in ejection fraction
In patients with heart failure due to idiopathic and ischaemic
cardiomyopathy, pentoxifylline use was associated with an
improvement in LVEF. In the Skudicky et al.5 (2000) trial of
patients with idiopathic dilated cardiomyopathy and NYHA
class II or III, there was a statistically significant improvement
in ejection fraction (OR 10.15, 95% CI: 1.96 - 52.69, p = 0.006).
Similarly, the Skudicky et al.6 (2001) trial also suggests that use
of pentoxifylline in the treatment of heart failure may be
beneficial, but the effect in this study was not statistically
significant (OR 3.42, 95% CI: 0.89 - 13.18, p = 0.07). The results
of the Sliwa et al.7 (2002) study point to the significant benefit
with the use of pentoxifylline in patients with severe heart
failure (i.e. NYHA class IV) due to idiopathic dilated
cardiomyopathy (WMD 8.40, 95% CI: 8.32 - 8.48).  These
findings have been extended to patients with heart failure of
varying severity due to ischaemic dilated cardiomyopathy
(WMD 8.10, 95% CI: 2.74 - 13.46, p = 0.003).9
Frequency of hospitalisation
None of the selected trials reported this endpoint. 
Mortality
Pentoxifylline was associated with a trend towards reduction
in mortality, but this was not statistically significant. In the
Skudicky et al.5 (2000) trial of 49 patients with NYHA II - III
heart failure due to idiopathic dilated cardiomyopathy,
treatment with pentoxifylline was associated with a potentially
large reduction in mortality of 74%, but this was not
statistically significant (OR 0.26, 95% CI: 0.05 - 1.45, p = 0.12).
A similar non-significant trend was found in another group of
39 patients with NYHA class II - III idiopathic dilated
cardiomyopathy (OR 0.59, 95% CI: 0.09 - 4.01, p = 0.6);6 18
patients with NYHA class IV idiopathic dilated
cardiomyopathy (OR 0.44, 95% CI: 0.03 - 5.93, p = 0.5);7 and
NYHA class I - IV ischaemic dilated cardiomyopathy (OR 0.18,
95% CI: 0.02 - 1.83, p = 0.15).9
Discussion
We conducted a systematic review of randomised controlled
trials in order to determine the effectiveness of pentoxifylline in
patients with heart failure.  Despite a systematic and thorough
search of the available literature, we identified only 4 small
randomised controlled trials with a total of 144 patients which
tested the effectiveness of pentoxifylline in heart failure.4-7,9 Our
findings suggest that pentoxifylline may be effective in
improving the symptoms (measured by NYHA functional
class) and cardiac function (measured by LVEF) in people with
heart failure due to idiopathic and ischaemic cardiomyopathy.
Pentoxifylline also had a promising effect on mortality, but this
effect was not statistically significant.
It is important to consider the limitations of the evidence
currently available.  The existing trials included a small
number of patients, suggesting that they may not provide
reliable and robust estimates of the effect of pentoxifylline on
important outcomes, such as mortality. Although the overall
quality of trial design was adequate, randomisation, allocation
concealment methods and loss to follow-up were not
adequately recorded in all studies. A large multicentre study
may be able to overcome the limitations of the present studies,
and provide conclusive evidence on the effectiveness of
pentoxifylline in reducing the risk of death in people with
heart failure.
Implications for practice
On the basis of the currently available evidence, pentoxifylline
cannot yet be recommended for routine use in patients with
heart failure.  
Implications for research
There is a need for a large, multicentre, prospective
randomised controlled trial to assess the effectiveness of
pentoxifylline in heart failure management.  Careful attention
ought to be paid to the drug’s influence on hard endpoints,
such as mortality and frequency of hospitalisation.  Such a trial
should include patients with heart failure of varying aetiology
and severity.
This review was prepared as part of a student study module
convened by Dr Sue Jessop of the Faculty of Health Sciences,
University of Cape Town in July/August 2003.  Bongani Mayosi
was funded by the South African Medical Research Council and
the University of Cape Town.
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